Identification of the mechanism of sensitization of human ovarian cancer cells to anticancer drugs by the DNA double strand breaks inhibitors
2016/23/N/NZ7/02023
Keywords
Descriptors
- NZ7_14: Farmacja, farmakoterapia, farmakologia
Panel
NZ7 – Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution
Uniwersytet Łódzki, Wydział Biologii i Ochrony Środowiska
Voivodeship: łódzkie
Principal investigator (from the host institution)
Number of co-investigators in the project: 2
Call
PRELUDIUM 12 – announced on 2016-09-15
- Amount awarded
- 148 800 PLN
- Project start date
- 2017-10-12
- Project end date
- 2021-10-11
- Project duration
- 48 months (the same as in the proposal)
- Project status
- Project settled
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
Publication in academic press/journals (1)
-
DNA Double-Strand Break Repair Inhibitors: YU238259, A12B4C3 and DDRI-18 Overcome the Cisplatin Resistance in Human Ovarian Cancer Cells, but Not under Hypoxia Conditions
- Authors:
- Anna Macieja, Izabela Gulbas, Tomasz Popławski
- Academic press:
- Current Issues in Molecular Biology (year: 2023, volume: 45(10), pages: 7915-7932), Publisher: MDPI (Multidisciplinary Digital Publishing Institute)
- Status:
- Published
- DOI:
- 10.3390/cimb45100500 – link to the publication